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Abstract
Background: Tuberculin skin testing is simple and relatively inexpensive, but the specificity of PPD is affected by BCG
vaccination.
Objective: Determine optimal dose and specificity of recombinant ESAT-6 and CFP-10 (C-Tb) produced in Lactococcus lactis
for diagnosis of M. tuberculosis infection.
Methods: In a dose finding phase I trial 0.01 or 0.1 mg preserved and unpreserved C-Tb was injected by Mantoux technique
in 38 patients with active tuberculosis and induration responses measured. In a phase II specificity trial in 151 uninfected,
BCG vaccinated participants 0.1 mg C-Tb was compared to 2 TU PPD.
Results: 0.1 mg C-Tb gave a median induration of 15 mm after 2 days. Phenol preservation did not affect the response. The
specificity of C-Tb was 99.3% (95% CI 96–100%) regarding indurations $5 mm as a positive outcome. This was higher than
the specificity of PPD (63% using a cut-off of 5 mm or 92% using a cut-off of 15 mm to adjust for non-specific BCG
responses). Local adverse reactions following C-Tb injection included transient itching and discomfort as expected
components of the immune response.
Conclusion: C-Tb offers a simple and convenient skin test to diagnose M. tuberculosis infection using a single, universal cut-
off unaffected by BCG vaccination.
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Introduction
Tuberculosis (TB) constitutes an enormous global burden with
8.7 million new cases and an estimated 1.4 million deaths in 2011
[1]. Pulmonary TB disease develops in between 5 to10% of
exposed individuals within 1–2 years after exposure [2,3], and is
defined by Mycobacterium tuberculosis (MTB) positive samples from
sputum or infected tissues [4,5]. Asymptomatic, latent TB
infection may reactivate at a later stage, particularly if the
individual acquires immunodeficiency from HIV. In low preva-
lence countries a predominant goal is to detect and treat latent TB
in order to achieve the stage of TB elimination. This includes
testing high risk groups such as close contacts of an active TB case,
HIV-infected, and children below 5 years of age [6,7]. There is no
gold standard for the diagnosis of latent TB. Many guidelines
include Tuberculin Purified Protein Derivative (PPD) and the
interferon-c release assays (IGRAs) QuantiFERONH-TB Gold In
Tube (QFT-IT, Cellestis, Carnegie, Australia) and T-SPOTH.TB
(Oxford Immunotec, Abingdon, UK) for the detection of latent
TB, either alone or in combination [4,8,9].
Tuberculin skin testing (TST) has been used for a century [10].
It is a ‘‘low tech’’ procedure resulting in an induration typically
10–20 mm in diameter at the injection site of an MTB infected
patient [11–13]. TST can be delivered and interpreted by point-
of-care medical, nursing or paramedical staff, has no need for a
laboratory, with a sensitivity around 75–90% [11,13]. Reactivity
to PPD may appear around 6 weeks after exposure to MTB [14].
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PPDs main disadvantage is its cross-reactivity with environmental
mycobacteria and all BCG vaccine strains. To compensate for this
cut-off points between 5 and 15 mm of induration are recom-
mended in various guidelines [6,15]. However, if infected with
HIV a low cut-off point may be used in spite of known BCG
vaccination. This gives rise to a complex interpretation of PPD
results with numerous local variations and clinical uncertainties.
The IGRAs are blood based in vitro assays based on peptides
covering the MTB specific, BCG-deleted antigens ESAT-6 and
CFP-10 giving specificities of 98–100% [16]. Due to costs and
complexity the World Health Organization issued in 2011 a
‘negative’ policy statement with a caution against replacing TST
by IGRAs as public health intervention to detect latent MTB
infection in low- and middle-income settings [17]. As discussed in
a recent workshop there is a need for an improved skin test [18].
C-Tb is a skin test for the diagnosis of MTB infection applied in
the same way as PPD but using ESAT-6 and CFP-10 produced as
recombinant proteins in Lactococcus lactis.
We report here (i) a phase I trial to determine an optimal dose of
C-Tb and to compare unpreserved and phenol preserved C-Tb
when testing patients with active tuberculosis, and (ii) a phase II
trial to investigate the specificity of C-Tb in uninfected, BCG
vaccinated participants which represent two key populations in
which a TST must operate for clinical diagnosis of active or latent
TB.
Materials and Methods
C-Tb
C-Tb was manufactured by SSI, Denmark according to Good
Manufacturing Practice as a solution of recombinant ESAT-6
(dimer) and CFP-10 mixed in a weight ratio of 1:1. Both antigens
derived from M. tuberculosis were cloned and expressed in
Lactococcus lactis [19]. For blinding purposes C-Tb were filled in
identical 10 dose vials as PPD RT 23 SSI and appeared as
indistinguishable clear, colourless solutions. C-Tb was injected by
the Mantoux technique as previously described [20].
QFT-IT
In vitro IFNc responses were measured in blood samples prior to
administration of C-Tb. An IFNc response $0.35 IU/ml was
regarded positive indicating MTB infection, negative ,0.35 IU/
ml. The result was indeterminate if the positive mitogen control
minus blank was ,0.5 IU/ml. Results above 10 IU/ml were
reported as 10 IU/ml. In the specificity trial in healthy volunteers,
additional blood samples for QFT-IT measurements were
collected 28 days (and 6 months) after skin testing.
Study Designs
The two double-blind studies described here were designed as
within-subject paired comparisons in which two skin test agents
were randomized in blocks of 10 or 12 to the left or right forearm
of each participant. Vials of each agent were put in boxes
numbered in succession and the volunteers were given intradermal
injections of 0.1 mL by Mantoux technique in their order of
appearance. In the dose-finding trial preserved (0.5% phenol) and
unpreserved C-Tb (doses of 0.01 mg and 0.1 mg per 0.1 mL) were
compared. In the specificity trial 0.1 mg C-Tb (preserved with
0.5% phenol) was compared with a standard 2 TU PPD RT
23 SSI dose.
The protocols for the two trials and supporting CONSORT
checklist are available as supporting information; see Checklist S1
and Protocols S1 and S2.
Dose-finding Trial
The dose-finding trial was conducted from February to
November 2010 at the Centre for Infection at St. George’s
University of London, United Kingdom and included 38 adults.
The recruited patients were diagnosed with active TB with a
compatible clinical picture of TB with the intention to treat
(Table 1). Participants were recruited from outpatient clinics in the
South West area of London within the first 2 month of acute phase
of antibiotic treatment and included with a positive culture, PCR
result, smear microscopy, or IGRA result. Treatments with
products likely to modify the immune response (e.g. corticosteroids
or blood products) or HIV infection were exclusion criteria. The
patients were recruited in 3 groups of 12. The first group received
0.01 mg preserved and unpreserved C-Tb in either arm according
to a randomization code. Based on an evaluation of safety and skin
reactions the last two groups received the same dose of 0.1 mg.
Follow-up visits took place after 1, 2, 3, 4, and 28 days and
included measurements of indurations and erythema. Immediate
pain caused by the injections was assessed by a Visual Analogue
Scale (VAS) using a ruler (Schlenker Enterprises LTD). The ruler
transformed various degrees of pain visualized by smileys into a
scale from 0 mm (no pain) to 100 mm (worst possible). Blood
samples for haematology and biochemistry analyses were collected
at baseline screening within 28 days before skin testing and at last
visit 21–32 days after testing.
Specificity Trial
The specificity trial was conducted from May to November
2011 at the Surrey Clinical Research Centre, Guildford, United
Kingdom and included 151 healthy, BCG vaccinated adults. The
most important exclusion criteria were history of TB or close
contact to a person with active TB, a positive QFT-IT at inclusion,
immunosuppressive treatment, congenital and/or acquired im-
mune deficiency or pregnancy. C-Tb and PPD were injected by
Mantoux technique and the diameter of any induration measured
after 2–3 days. All systemic and local adverse events occurring
within 28 days were recorded. Laboratory safety parameters of
haematology and biochemistry and a 2nd QFT-IT were performed
on day 28. An IFNc response occurring at this time point was
regarded an immune reaction to C-Tb/PPD and an additional
blood sample was collected after 6 months for a repeated
measurement to investigate the duration of the response.
Table 1. Distribution of primary site of tuberculosis infection
and number of patients in dose-finding trial.
C-Tb dose group (/0.1 mL)
TB diagnose 0.01 mg 0.1 mg
Pulmonary 6 (50%) 13 (50%)
Lymph node 0 (0%) 6 (23%)
Pleural 2 (16%) 2 (8%)
Spinal 3 (25%) 0 (0%)
TB meningitis 0 (0%) 1 (4%)
Other1 1 (8%) 4 (15%)
Total 12 26
1Including disseminated/miliary TB.
doi:10.1371/journal.pone.0064215.t001
Dose and Specificity of C-Tb
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Sample Size Calculation
The sample size of 12 (24) in the dose finding trial was mainly
based on practical considerations. However, a group of 12 (24)
volunteers gave 72% (92%) chance of discovering an unacceptable
adverse reaction appearing at a true frequency of 10%.
The specificity was estimated as a relative frequency in a
binomial distribution. With N patients the variance of the
estimated specificity (uˆ) is Var(uˆ) = u(1–u)/N, where u is the
(unknown) true specificity. For a fixed value of N Var(uˆ) obtains its
maximum when u=0.5. With N=150 this maximum is 0.25/
N=0.0017 corresponding to a standard deviation SD(uˆ) of 0.041.
As the true specificity is expected to be higher than 0.5 the
standard deviation of 0.041 is a worst case scenario. With a more
realistic value for the true specificity of 0.8 the corresponding
standard deviation becomes 0.033, which was considered an
acceptable precision of the estimate.
Data Safety Monitoring Board
A Data Safety Monitoring Board consisting of four independent
senior clinicians was established for the dose-finding trial to
evaluate adverse reactions prior to proceeding to the next strength
of C-Tb.
Ethics Statement
The trials were conducted according to ‘‘Note for guidance on
good clinical practice’’, CPMP/ICH/135/95, ICH topic E6 and
CPMP/ICH/377/95 E2A and in accordance with the ethical
principles of the edition of the Declaration of Helsinki, adopted at
the 59th World Medical Association General Assembly, Seoul, in
October 2008. For both trials written informed consent was
obtained prior to inclusion. The dose-finding trial was approved
by The Royal Marsden Research Ethics Committee (No 09/
H0801/90) and The Medicines and Healthcare Products Regu-
latory Agency (MHRA; No. 17282/0204/001-0001). The speci-
ficity trial was approved by the NRES Committee London – East
& City (No 10/H0703/109) and by MHRA (No 17282/0205/
001-0001). The trials were filed in the NIH clinical trials database
NCT01033929 and NCT01241188.
Results
The dose-finding trial included 38 TB patients (23 males) with
mean age of 33 years (18–60). All patients were included in the
safety analyses and 35 patients were included in analysis of skin test
reactions (Figure 1). 16 patients (46%) had a culture or PCR
confirmed TB at inclusion, 4 (11%) were included based on a
positive smear, 8 (23%) on a positive T-SPOTH.TB and 7 (20%)
on a positive QFT-IT. One patient retrospectively failed the
inclusion criteria as sputum culture revealed M. kansasii instead of
M. tuberculosis infection. This patient showed no response to
0.01 mg C-Tb. Two patients were inappropriately enrolled due to
immune suppressive medication (steroid treatment) and were
subsequently replaced. 20 patients (53%) had a history of BCG
vaccination and 18 (47%) had received a TST 7–80 days prior to
the study as part of the TB diagnostic process.
The specificity trial included 151 healthy, BCG vaccinated
participants (59 males) with a mean age of 34 years (18–65). 135
were classified as white, 4 as black, 9 as Asian, and 3 as other. All
patients were included in the safety analyses and 147 were
included in analysis of skin test reactions (Figure 2).
Protocol Deviations
In the dose finding trial the pain associated with the injection
was assessed 1 h after the administration answering the question
‘‘How painful did you experience the injections?’’ scored
according to the VAS scale. 16 patients in the 0.1 mg dose group
were in error asked ‘‘How painful do you experience the pain now
after 1 h?’’.
Dose Response of C-Tb in TB Patients
The induration response peaked after 2 days with a median
response of 14.5 mm (0.1 mg C-Tb, Figure 3). The responses
remained visible at day 4. TST performed prior to the present trial
in 18 of the tuberculosis patients showed a median response of
15 mm (5–22 mm). The median responses with 0.01 mg C-Tb
were below 5 mm. A dose of 0.1 mg C-Tb was chosen for
succeeding trials to give a response similar in size to the one of
PPD. Maximum responses with C-Tb ranged between 4–23 mm
(0.01 mg) and 10–40 mm (0.1 mg). No skin reactions were apparent
after 1 month in either dose group.
Effect of Phenol Preservation on C-Tb in TB Patients
The size of induration was not affected by phenol (Figure 4;
Wilcoxon’s Signed Rank: P.0.05). Phenol (0.5%) preservation of
C-Tb did not influence the immediate pain associated with the
injection. Thus, 10/22 patients experienced no difference in VAS
score between the left and the right arm. Among the remaining 12,
five experienced less pain with the phenol preserved formulation.
The pain seemed to disappear within the first hour after the
injection as reported by 13/16 patients.
Comparison between C-Tb and QFT-IT Assay in TB
Patients
In the dose finding trial C-Tb (0.1 mg) and QFT-IT showed
concordant results in 18/22 patients (82%, Figure 5A). The
magnitude of the responses were positively related (R=0.54,
Figure 5B) with a slope of the regression line of 1.4 mm?ml/IU
significantly different from zero at the 5% level. In 3/22 cases
inclusion was based on a positive QFT-IT result giving a bias if
used in a comparison with C-Tb. In the remaining 19 cases where
inclusion was based on other criteria, C-Tb and QFT-IT showed
moderate agreement with concordant results in 15/19 cases
(k=0.51). In four cases of lymph node (2) or pulmonary TB (2) the
two test systems gave discordant results: two C-Tb positives (one
lymph node, one pulmonary) tested negative with QFT-IT
(0.13 IU/ml and 0.31 IU/ml), and two QFT-IT positives
(1.33 IU/ml and 2.19 IU/ml) gave no induration with C-Tb.
Three of those had culture confirmed TB, whereas one testing
negative with C-Tb and positive with QFT-IT had a positive
smear. The two indeterminate results with QFT-IT included with
a positive T-SPOTH.TB had pleural or lymph node TB. Four
patients tested negative with both tests: two included with a
positive culture and two with a positive T-SPOTH.TB.
Interaction between C-Tb/PPD and QFT-IT Assay in
Unexposed, BCG-vaccinated Adults
To ensure a low risk of MTB infection all participants in the
specificity trial were included as QFT-IT negative at entry
(,0.35 IU/ml). At the end of the trial (26–30 days later) five
had become QFT-IT positive and one had an indeterminate result
(Table 2). Two of those had a baseline result of 0.024 and
0.064 IU/ml respectively, the rest were #0 IU/ml. In all five
positives the responses were negative when retested after 6 months.
Three of the five had an induration response to PPD of 9, 9 and
10 mm, but none had an induration response to C-Tb.
Dose and Specificity of C-Tb
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Specificity of C-Tb in Healthy BCG-vaccinated Participants
The specificity of C-Tb and PPD was defined as the relative
frequency of induration responses below a given cut-off measured
two to three days after injection to participants with no known
exposure to MTB. Of the 147 participants in the per-protocol
population included with a negative QFT-IT result, 143 partic-
ipants (97.3%) showed no induration to C-Tb (Figure 6 A). One
participant had an induration of 3 mm, two of 4 mm, and one of
9 mm. None of the four participants showing an induration to C-
Tb had a response to PPD and they all remained QFT-IT
negative. An optimal cut-off for C-Tb will be based on the
Figure 1. Flow diagram of dose-finding trial. TB patients received C-Tb (unpreserved and phenol preserved) in either arm. 3/11 (0.01 mg C-Tb)
and 13/24 (0.1 mg C-Tb) had a culture or PCR confirmed TB at inclusion, the rest were smear (2/11 and 2/24) or IGRA (6/11 and 9/24) positive.
doi:10.1371/journal.pone.0064215.g001
Figure 2. Flow diagram of specificity trial. BCG vaccinated,
healthy, QFT-IT negative participants received 0.1 mg C-Tb and 2 TU
PPD RT 23 SSI in either arm.
doi:10.1371/journal.pone.0064215.g002
Figure 3. Time course of the induration response to preserved
C-Tb in patients with active TB. The median induration response
(line within boxes) is shown for the first 4 days after injection of TB
patients with 0.01 mg (white; N= 11) or 0.1 mg C-Tb (grey; N = 24) in
dose-finding trial. The boundaries of boxes are 25th and 75th percentiles.
Error bar indicate 90th percentile.
doi:10.1371/journal.pone.0064215.g003
Dose and Specificity of C-Tb
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specificity trial reported here and a sensitivity trial in TB patients.
Preliminary results indicate the cut-off of C-Tb to be 5 mm.
However, any induration will correspond to a specificity of 97.3%
(95% CI 93.2–99.3%) and 5 mm to a specificity of 99.3% (95% CI
96.3–100.0%; Figure 6B) for C-Tb. The specificity of PPD was
62.6% [95% CI 54.2–70.4%] using a cut-off of 5 mm, increasing
to 76.9% [69.2–83.4%] and 91.8% [86.2–95.7%] using cut-offs of
10 and 15 mm respectively.
Adverse Reactions to C-Tb in TB Patients
No C-Tb-related serious adverse events in tuberculosis patients
occurred during the 28 days trial period. 31 of 38 experienced one
or more adverse events of which the most common were itching
and pain at the injection site (Table 3). These reactions were more
frequent with the high dose of C-Tb.
All injection site reactions categorised as at least possibly related
to C-Tb recovered within 28 days except from hyperpigmenta-
tions reported by two patients. Systemic events with 0.01 mg C-Tb
(12 patients tested) included moderate night sweats (1), moderate
rash on neck (1), and ‘feeling feverish’(2). Systemic events with
0.1 mg C-Tb (26 patients tested) included ‘feeling feverish’ (2),
headache (1). One patient reported rash/warm/itchy/slightly
swollen/pain. All systemic events categorised as at least possibly
related to C-Tb recovered within 28 days, and are also compatible
with underlying tuberculosis and treatment. No clinically signif-
icantly abnormal laboratory results related to C-Tb were recorded.
Adverse Reactions to C-Tb in Unexposed, BCG-
vaccinated Adults
No serious adverse events or events of severe intensity occurred
during the specificity trial. Among 151 participants 48 (32%)
experienced an adverse injection site reaction at the C-Tb
injection site, versus 31 (21%) at the PPD injection site
(p = 0.036). All C-Tb adverse injection site reactions were of mild
intensity.
Figure 4. Induration 2 days after injection of unpreserved and
phenol preserved C-Tb (0.1 mg) to TB patients. Line of identity is
shown. Area of dot indicates number of patients with dot at (0.0)
representing 7 participants. N = 24.
doi:10.1371/journal.pone.0064215.g004
Figure 5. QFT-IT and C-Tb responses in patients with active TB. QFT-IT positive-negative result (panel A) and baseline concentration of IFNc
(panel B) at screening versus induration diameter 3 days after injection of 0.1 mg preserved C-Tb to TB patients (N = 24). Indeterminate (Ind) results are
omitted in panel B. Dotted lines represents cut-off values. Regression line is shown in panel B.
doi:10.1371/journal.pone.0064215.g005
Table 2. IFNc among responders to C-Tb/PPD 1 and 6
months after skin testing in specificity trial.
QFT-IT (IU/ml) Skin test (mm)
Subject Baseline 1 month 6 months PPD RT 23 C-Tb
S565 0.064 0.746 0.119 0 0
S578 0.024 0.354 20.021 10 0
S676 20.042 13.911 20.005 0 0
S700 20.009 3.435 0.045 9 0
S702 0.000 0.832 0.000 9 0
doi:10.1371/journal.pone.0064215.t002
Dose and Specificity of C-Tb
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Haematoma at the C-Tb site was the most common, accounting
for 38 of the 48 reported adverse reactions. Seven participants
(4.6%) reported a systemic adverse reaction assessed as possibly
related to administration of the two skin tests. All systemic adverse
events were of mild or moderate intensity. No clinically
significantly abnormal laboratory results were recorded.
Discussion
Using treated TB patients as surrogate for a latent infection we
previously showed proof of principle for the C-Tb test using only
rdESAT-6 [21]. It was found that 0.1 mg rdESAT-6 gave an
induration similar in size to 2 TU PPD RT 23 SSI. To increase
sensitivity rCFP-10 was subsequently included in C-Tb [22]. In a
first-in-man trial C-Tb showed no signs of false positive reactions
(no sensitisation) if healthy participants were tested twice 6 weeks
apart corresponding to the incubation period of TB [20]. In MTB
infected guinea pigs C-Tb showed the same dose response as
previously described with rdESAT-6 (data not shown) [19]. Yet, as
a safety precaution the initial dose of C-Tb was reduced to 0.01 mg
in the dose finding trial described here because this study took
place in TB patients with a risk of more adverse reactions and
stronger responsiveness than in treated cases. PPD was not
included as direct comparator as it might already have been
applied during diagnostic workup giving a risk of a booster
response [13]. However, indurations with 0.1 mg C-Tb were
similar to those reported previously for PPD [12,13]. When used
in standard doses in patients with active TB, PPD may induce
painful responses with ulceration. It was therefore reassuring that
in this population of active TB cases, C-Tb was associated with
few, minor adverse reactions, of which itching and pain were the
most frequent and probably inevitable parts of the diagnostic
immune response.
For optimal cost effectiveness C-Tb could be distributed in
multi-dose vials, so C-Tb was preserved with 0.5% phenol to
comply with the European Pharmacopoeia on antimicrobial
efficacy. It is encouraging therefore that phenol did not seem to
give rise to unspecific indurations or affect adverse reactions in
patients with active tuberculosis tested with C-Tb. This concurs
with two studies done in 2000 investigating unpreserved and
phenol preserved PPD RT 23. The studies included 209 healthy
participants and 55 TB patients in Lithuania and 319 healthy
participants in Sweden. Similar immune responses were observed,
but VAS scores showed more pronounced immediate pain with
the unpreserved preparation (SSI unpublished data). In the
present study the numbers were too low to verify a positive
influence of phenol on the injection site pain. This may partly be
due to the fact that 16/38 patients were asked a differently phrased
question about the pain during the conduct of the trial.
In the specificity trial four of the 147 QFT-IT negative, healthy
participants had an induration response with C-Tb. As there is no
gold standard to identify latent TB it cannot be ruled out that
some of the responders may be true C-Tb positives. The
participant with a 9 mm C-Tb response worked as an ambulance
technician, and although he did not give a specific history of
contact with a known TB case, one could speculate that this
occupation may expose him to an increased risk of contact with a
contagious case of TB. Nonetheless, our data suggest a specificity
of C-Tb of 99% at a cut-off 5 mm. This is similar to the
specificities reported for the blood-based IGRAs [9,16]. In
comparison a specificity of 92% was seen with PPD RT 23 using
a cut-off of 15 mm to compensate for non-specific contribution to
the induration response by prior BCG vaccination. Because QFT-
IT was part of the inclusion criteria to ensure a low risk of MTB
Figure 6. Distribution of induration responses and specificity of C-Tb and PPD in healthy BCG-vaccinated adults. The induration
responses 2–3 days after testing with 0.1 mg C-Tb (black bars) and 2 TU PPD RT 23 SSI (grey bars) are shown in panel A. The resulting specificity of C-
Tb (solid line) and PPD RT 23 SSI (broken line) as a function of cut-off is shown in panel B. N: 147.
doi:10.1371/journal.pone.0064215.g006
Table 3. Local adverse reactions within 28 d after injection of
unpreserved and phenol preserved C-Tb.
0.01 mg C-Tb1 0.1 mg C-Tb2
Local reaction Unpreserved Preserved Unpreserved Preserved
Itch 6 (50%) 3 (25%) 17 (65%) 16 (61%)
Pain 2 (17%) 1 (8%) 8 (31%) 6 (23%)
1N= 12.
2N= 26.
Patients in dose-finding trial were in treatment for active TB.
doi:10.1371/journal.pone.0064215.t003
Dose and Specificity of C-Tb
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infection, a direct comparison of C-Tb and QFT-IT was not
possible due to bias.
Based on the prevalence of childhood BCG immunization
different regions employ different cut-offs for PPD, so it is evident
that use of a single cut-off for C-Tb irrespective of BCG status will
simplify the interpretation of a skin reaction.
C-Tb and QFT-IT takes advantage of the same antigens, and
the trials described here indicate a similar performance of the two
tests. However, in four cases in the dose-finding study C-Tb and
QFT-IT showed discordant results in patients confirmed by
culture or smear. Discordance could not be explained by the site of
infection as both groups were represented by one case of lymph
node and one case of pulmonary TB. Part may be related to the
definition of positive test result as one testing positive with C-Tb
showed an IFNc result of 0.31 IU/ml slightly below the cut-off for
QFT-IT. Another reason could be difference in incubation time,
overnight for QFT-IT vs. 2–3 days for C-Tb, which could affect
the sensitivity. The degree of discordance between C-Tb and
QFT-IT of 18% was of the same magnitude as previously reported
for QFT-IT and T-SPOTH.TB [23]. Four TB patients tested
negative with C-Tb and QFT-IT. Genetic factors may be involved
in their lack of reactivity [24].
As skin testing and IGRAs may both be used in clinical practice
we sought to investigate the effect of C-Tb and PPD injections on
the QFT-IT. In the specificity trial five participants developed a
temporary QFT-IT response. It was not possible to discriminate if
this was due to boosting or a false positive reaction.
By combining the high specificity of the costly and technically
complex IFNc release assays with the low tech procedure of
tuberculin and a single cut-off, C-Tb may become a valuable tool
for the detection of MTB infection by point-of-care staff. Two
phase III trials have been initiated to investigate the performance
of C-Tb in groups who are known to be at higher risk of
developing tuberculosis including close contacts to pulmonary TB
cases, children below 5 years of age and HIV-infected.
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